Trodelvy's FDA Approval Highlights Cybersecurity Risks in Healthcare Data Infrastructure
The article examines the cybersecurity vulnerabilities exposed by the FDA approval of Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. While the clinical breakthrough is significant, the author argues that the digital infrastructure supporting such t
